Why the study?
The epidemiology, assessment, and treatment landscape of pulmonary arterial hypertension have changed remarkably over the last three decades, warranting an updated perspective on assessment and newer therapies.
Answers are grounded in this paper and cite their sources.
This review summarizes the evolving epidemiology of PAH and the current standard of care involving early identification, risk stratification, and upfront combination therapy.
Pulmonary arterial hypertension (PAH) is a rare condition for which a remarkable change has been witnessed in the epidemiology, assessment and treatment landscape over the last three decades. Well-established registries from the Western world have not only highlighted the shift in the epidemiology to an older, more comorbid cohort but have also identified markers of prognosis that have been validated as part of risk stratification scores in multiple cohorts. The emphasis on early identification through a systematic assessment pathway and the option of upfront combination therapy with serial risk stratification assessment has laid the foundation for the standard of care and improved prognosis. This review provides an update on the assessment and newer therapies for PAH.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: